Skip to content

IMPORTANT NOTIFICATION: Zantac (Ranitidine) Recall

Dear Doctor, Aspen Pharmacare Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA), is conducting a retail level recall of Zantac (ranitidine) tablets, effervescent tablets, syrup and ampoules. The TGA has not requested that a Dear Doctor letter be sent for this retail level product recall. We are informing you as the potentially…

Read More

ANNOUNCEMENT – Aspen AstraZeneca Anaesthetics Portfolio Agreement

Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”).

Read More

Ferinject® (ferric carboxymaltose) 10ml (500mg) available on the Pharmaceutical Benefits Scheme (PBS) from the 1st June, 2014

Aspen Australia is pleased to advise that from the 1st June, 2014 Ferinject® (ferric carboxymaltose) 10ml (500mg) is available on the Pharmaceutical Benefits Scheme (PBS) as a drug for iron deficiency anaemia.# Ferinject® (ferric carboxymaltose) is available in Australia for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis must be based on laboratory tests.

Read More

Aspen to distribute Merck products

Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.

Read More
Scroll To Top